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Summary Over a 10 year period, between 1974-1984, 257 adult cases of tissue sarcoma have been evaluated
in the Department of Medical Oncology, Christie Hospital, Manchester. At registration locally advanced or
metastatic diseases was present in 162 (63%). The male/female ratio was 1.5:1 and median age 54 years (range
14-85). The commonest sites were lower limb (33%), visceral (21%), trunk (13%), retroperitoneum (12%)
and upper limb (10%). Leiomyosarcoma (27%), liposarcoma (14%) malignant fibrous histiocytoma (10%)
and neuro plus fibrosarcomas (15%) were the most frequent histological subtypes. A high proportion of
uterine sarcomas (17%) is a point of distinction from many other series. Histological grade was specified in
72% of cases and the distribution (Grade 1-27%; 11-6%; 111-67%) reflected a referral bias towards
advanced disease. Local resection of the primary tumour was performed in 76% of cases.In many instances
this only amounted to 'shelling out' and true compartmental excisions were rare. Amputation was performed
in 31% of patients with limb sarcomas. Ninety-eight patients (38%) had experienced one or more local
recurrences prior to referral and the overall local recurrence rate was 56%. Suitable patients (78%) received
chemotherapy, 50% entering multicentre trials in collaboration with the EORTC. The commonest regime
used in patients with advanced disease was CYVADIC which produced an overall response rate of 37%.
Ifosfamide, used as a single agent in 16 patients, induced 3CR and 5PR for an overall response rate of 50%.
When used in combination with MTX and VADIC, there was no difference in response rate, but numbers in
these pilot studies were small. Seventeen high risk patients received adjuvant chemotherapy with VAC, but the
results (11 relapses) were disappointing. An EORTC trial, comparing adjuvant CYVADIC chemotherapy
with control has acrrued 307 patients, 49 of these from the Christie Hospital.
Preliminary results within this centre - 13/25 relapses in the control arm, 5/23 in the chemotherapy arm -
suggest an advantage for chemotherapy but the data are statistically not significant. Post-operative radical
radiotherapy after resection of the primary tumour or local recurrence was performed in 51 patients, with
local control in 65% of cases, although metastases developed in 41%. At the time of analysis (1st April 1984)
98 (38%) were alive, of whom 72 showed no evidence of disease and 52 had never relapsed. Malignant disease
was the cause of death in 92%. Overall survival was not influenced by sex, but patients less than 40 years of
age fared significantly better (P<0.001). Survival was better for patients with sarcomas of the extremities and
trunk than for visceral tumours, whereas those in the head, neck, thorax and peritoneum did significantly
worse (P<0.001). As shown in many other series, histological grade had a highly significant influence on
survival (P<0.001), in favour of low grade (I) tumours, whereas histological subtype was unimportant
(P=0.22). Although the incidence of local recurrence did not relate to pathological size, larger tumours
(> 100cm2) had a higher rate of metastasis and poorer survival. Local recurrence was also associated with a
poorer survival (P=0.03). For high grade tumours, patients treated by amputation fared better than those
whose tumour was locally resected. The overall rate of local recurrence was 56% and metastasis 62%.
Rhabdomyosarcomas (79%), synovial sarcomas (79%) undifferentiated (75%) and leiomysarcomas of the
uterus (79%) showed an increased propensity for metastasis, in contrast with fibrosarcomas (39%) and
liposarcomas (43%). Neurofibro-and fibrosarcomas had the highest rates of local recurrence (71%). However
numbers in all these groups were small. Metastasis from sites in the head and neck (45%) and
retroperitoneum (43%) was less frequent but local progression often occured. Visceral tumours showed a low
rate of local relapse (41%) but a high incidence of metastasis (81%). The commonest sites of metastasis were
lung (57%) and intra-abdominal (16%).
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The extensive literature on soft tissue sarcoma is
disproportionate to their incidence - less than 1%
of all malignant tumours. Although primary
management is usually surgical, their ubiquitous
distribution in the body means that these tumours
present to several disciplines. Many simulate more
common benign tumours, and highly variable
histological appearances can make diagnosis
difficult. Although radical surgery may achieve
local control, combined modality therapy may
allow a more conservative approach, and addresses
the problem of metastases. Referral to specialist
centres, where there is interest and expertise in the
management of these tumours, is therefore
desirable.
The surgical management, particularly of limb
sarcomas, has been explored in a number of large
series (Shiu et al., 1975; Simon & Enneking, 1976;
Rantokokko & Ekfors, 1979, Markhede et al.,
1982) and the relationship of local recurrence to
adequacy of resection is clearly defined. Series of
sarcomas at specific sites (Braund & Pigott, 1962;
Salazar et al., 1978a; Cody et al., 1981; Gerson et
al., 1982) have been reported. Conservative surgery
combined with adjuvant radiotherapy given pre-
(Suit et al., 1981) or post-operatively (Lindberg et
al., 1981; Weisenburger et al., 1981, Rosenberg et
al., 1982) has been extensively studied. More
recently the role of chemotherapy, in an adjuvant
setting (Sordillo et al., 1981; Weisenburger et al.,
1981; Das Gupta et al., 1982; Rosenberg et al.,
1982; Edmonson et al., 1982) or for advanced
disease (Gottlieb et al., 1975; Baker et al., 1979;
Yap et al., 1981; Presant et al., 1981; Saiki et al.,
1982; Borden et al., 1983) has been evaluated in
large multi-centre trials.
In the UK a number of authors (Cade, 1951;
Windeyer et al., 1966; Spittle et al., 1971; Coe et
al., 1981) have examined the role of post-operative
radiotherapy in the conservative management of
primary sarcomas. The Royal Marsden hospital has
reviewed its experience in the chemotherapy of
advanced disease between 1973-1979 (Wiltshaw et
al., 1979) but data on adjuvant chemotherapy in
Britain are limited.
The Christie Hospital, Manchester, is a specialist
Cancer Hospital, which serves a population of
-4.5 million people living in North-West England.
A review, carried out by Dr Charles Pratt during a
sabbatical at the Christie, (unpublished data), of
extremity sarcomas referred for radiotherapy
between 1955 and 1973, included 303 patients who
had a correct 5 year survival of 35% and 10 year
survival of 25%. Chemotherapy was only used in
4% of patients and was mainly single agent
Cyclophosphamide, Vincristine or Actinomycin D.
In 1974, a University Department of Medical
Oncology, supported by the Cancer Research
Campaign, was established at the Christie Hospital,
and the management of soft tissue sarcomas has
been a particular interest of this unit, especially
since 1977. This paper reviews our experience
during the first 10 years of the unit, with emphasis
on participation in collaborative European studies
in the management of primary and metastatic
disease.
Materials and methods
All adult patients (age> 16y) with soft tissue
sarcoma presenting to the Department of Medical
Oncology, Christie Hospital between 1st April 1974
and 1st April 1984, have been reviewed. It was not
possible to confirm the pathology in 17 patients
and these have been excluded from further analysis.
Pathological material was reviewed at the time of
referral to the Christie, by pathologists in the
University hospitals of South Manchester. Relevant
data have been entered on computer, initially
retrospectively, but on a prospective basis over the
past 5 years.
Although patients were occasionally referred for
an opinion after biopsy of the primary tumour
before definitive surgery, the majority were seen
after excision of the primary tumour, or when local
recurrence or metastatic spread was evident.
Eligible patients have been entered into
multicentre trials of chemotherapy in collaboration
with the Soft Tissue and Bone Sarcoma Group of
the European Organisation for Research and
Treatment of Cancer (EORTC). Single centre pilot
studies of combination chemotherapy have also
been performed. Other patients were considered
suitable for radical radiation therapy, with or
without adjuvant chemotherapy, and palliative
irradiation was given where indicated.
Recommendations for symptomatic relief only were
made for elderly patients with extensive disease, or
those in poor general condition.
The majority of patients receiving chemotherapy
or radiotherapy have been followed in out-patient
clinics, and for those that have died, the date and
cause are known. Information on the remaining
patients has been obtained through their general
practitioner, referring hospitals, and registration of
cancer deaths through the office of Population,
Census and Surveys (OPCS), or the National
Health Service central registry. Definition of
response are those outlined by the World Health
Organisation (WHO 1979).
Analysis of survival from date of first surgical
operation was carried out by the Log-Rank method
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Results
During the 10 year period, 1974-1984, 257
documented cases of soft tissue sarcoma have been
evaluated. At registration, 162 patients had locally
advanced or metastatic disease, while the remaining
95 were referred after definitive surgery for the
primary tumour or a local recurrence. The pattern
of referral according to year is shown in Figure 1.
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Figure 1 Pattern of referral to Christie Hospital: (0)
all patients (n=257); (0) no evidence of disease at
registration (n =95).
Patient characteristics
There were 154 males, 103 females, with a
median age (at the time of diagnosis of the primary
tumour) of 54 years, range 14-85. Presenting
symptoms are shown in Table I, the commonest
being a mass (79%) which had ulcerated in 4 cases
and was associated with pain, in 43% of cases. The
mean and median durations from first symptoms to
definitive treatment of the primary tumour were 12
and 5 months respectively but the range, 0-238
months, was wide.
The commonest sites were lower limb (33%)
visceral (21%), trunk (13%), retroperitoneum (12%)
and upper limb (10%). Table II presents the
distribution of histological type according to site,
and Table III provides more detailed information
Table I Presenting symptoms primary.
Patients
Symptoms No. %
Pain 112 43
Mass 203 79
Other 98 38
Menorrhagia or
post-menopausal bleeding 33
Urinary 13
Abdominal distension 6
Weight loss 6
Respiratory 8
Focal weakness 5
about site. Leiomyosarcoma was the most frequent
histological type, 41% (28 cases) of these being
uterine sarcomas. Leiomyosarcomas were also
commonest in the retroperitoneum (40%) followed
by liposarcomas (23%) and neurofibrosarcomas
(17%). In the proximal lower limb (including
buttock) liposarcomas (26%) predominated,
followed by synovial sarcomas (12%) and
malignant fibrous histiocytomas (11%).
Overall the commonest histological types were
leiomyosarcoma (27%), liposarcoma (14%)
malignant fibrous histiocytoma (10%) and fibro-
and neurofibrosarcomas (15%). Miscellaneous
histological types, of which mixed mesodermal and
endometrial stromal sarcomas of the uterus were
most prevalent, are shown in Table IV..
Histological grade was specified in 186 cases
(72%) the majority of cases being high grade (III) -
125 (67%), although 51 (27%) were low grade (I)
tumours. Intermediate grade (II) sarcomas were
uncommon- 10 (6%).
Clinical size, at presentation of the primary
tumour, was recorded in less than half (124) the
cases, and accurate measurements were rarely
made. Histological reports documented pathological
size in 159 cases (62%), but this was not available
for inoperable tumours or those removed
piecemeal. Sarcomas of unknown size had a higher
rate of local recurrence (65% vs 50%) and
metastasis (73% vs 55%) compared with tumours
of documented pathological size (Table V). The rate
of local recurrence did not seem to vary
significantly with pathological size except that only
one local relapse was observed in 6 tumours
>400cm2. Metastases tended to increase in
frequency with size up to 225cm2, with few
tumours (22) larger than this available for analysis.
Survival was linked to tumour size (Figure 2), those
patients with sarcomas > 100cms2 faring
considerably worse (P<0.01).304 V.H.C. BRAMWELL et al.
Table II Histological type according to site.
Histology
Head Distal Proximal Distal Proximal
& upper upper lower lower Retro- Intra- Total
neck limb limb limb limb Trunk peritoneum Visceral thoracic Other No. %
Angiosarcoma 3 0 1 0 2 3 1 0 0 0 10 4
Fibrosarcoma 1 0 1 1 6 5 1 0 2 0 17 7
Leiomyosarcoma 2 0 2 0 5 3 12 34 4 7 69 27
Liposarcoma 0 1 2 2 19 5 7 1 0 0 37 14
Neurofibro-
sarcoma 1 0 2 2 5 4 5 0 1 1 21 8
Rhabdomyo-
sarcoma 1 1 3 0 5 2 0 2 0 0 14 6
Synovial sarcoma 0 1 1 2 9 0 0 0 0 0 13 5
Undifferentiated 0 0 2 1 6 0 2 1 0 0 12 4
Malignant
fibrous
histiocytoma 2 2 5 1 8 4 2 1 0 2 27 10
Miscellaneous 1 0 1 4 8 7 0 15 1 0 37 15
TOTAL No. 11 5 20 13 73 33 30 54 8 10 257
% 4 2 8 5 28 13 12 21 3 4 100
Table III Detailed analysis of site.
1. Head and neck
Head
Neck
2. Distal upper limb
Forearm
Hand
3. Proximal upper limb
Upper arm
shoulder
4. Distal lower limb
Lower leg
Foot
5. Proximal lower limb
Thigh
Buttock
Groin
6. Trunk
Breast
Perineum
Abdominal wall
Chest wall
Loin/back
11 7. Retroperitoneum
8 8. Visceral
3 Uterus
5 Stomach
3 Bowel/mesentery
3 Ovary
20 9. Intrathoracic
10 Lung & pleura
10 Mediastinum
13 10. Miscellaneous
8 Paratesticular
5 Liver
73 Prostate
56 Cervical remnant
10 Broad ligament
7 Multicentric
33
10
2
3
11
7
30
54
42
3
3
6
8
4
4
10
2
3
1
1
2
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Table IV Miscellaneous histology.
Histological type No. patients
Mixed mesodermal ga
Endometrial stromal 5
Unclassfied 4
Epithelioid 3
Alveolar rhabdomyosarcoma (adult) 3
Osteosarcoma soft tissues 3
Mesenchymoma 2
Carcinosarcoma 2
Fibromatosis (metastasising) 2
Chondrosarcoma soft tissues I
Chordoid 1
Cystosarcoma phyllodes 1
Ewing's soft tissues l
a6 uterine, 3 ovarian.
Table V Pathological size related to local recurrence and metastasis.
aPathological size Local recurrence Metastases Total
(cms2) No. % No. % No. patients
0-24 19 54 12 34 35
25-99 24 40 34 57 60
100-224 24 57 29 69 42
225-399 11 69 9 56 16
400+ 1 17 3 50 6
TOTAL 79 50 87 55 159
Unknown 64 65 72 73 98
aLargest diameter multiplied by largest perpendicular diameter.
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Figure 2 Survival according to pathological size.
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Surgical treatment
Surgical management of the primary tumour
prior to referral to the Christie is described in Table
VI. Ninety-eight patients had experienced one (72
patients) or more (range 2-11) local recurrences in
the intervening period. Amputation was carried out
for 34/111 (31%) limb sarcomas.
Table VI Surgical treatment of the primary
tumour.
Patients
No. %
Resectability
Not resectable 28 11
Partially resectable 43 17
Totally resectable 186 72
Surgicalprocedure
Local resection 195 76
Amputation 34 13
Biopsy only 26 10
aNothing 2 1
aHistological diagnosis obtained from
lymph node metastases.
Chemotherapy
Suitable patients were entered into clinical trials
evaluating chemotherapy in advanced disease, or as
an adjuvant treatment following surgery with or
without radiotherapy. Table VII gives the
distribution of patients within these trials and
Tables VIII and XII describe the chemotherapy
protocols for advanced disease and adjuvant
therapy respectively.
Advanced disease
Christie studies Until 1976 patients with advanced
disease were treated with the CYVADIC regime
(Table VIII). Twenty-five patients received this
combination, but pathological material could not
be reviewed for three, and there was one early
death from malignant disease occuring at 2 weeks.
There were 3CR (14%) and 7PR (33%), giving
overall response rate of 47%. Durations of
remission were: CR 9, 11, 16 months; PR - median
9 months, range 4-27.
In 1982 a small pilot study of alternating
chemotherapy (Ifos/MTX VADIC Table VIII) was
initiated. Ten consecutive patients were entered into
this study, instead of EORTC protocols, and a
further 3 patients who lacked clinically measurable
disease (but could be evaluated by computed
tomography) have been added. There was one early
Table VII Clinical trials.
Patients
Trial entered
No. %
Christie
CYVADICa 22+6b 9
VAC 19 7
IFOS/MTX-VADIC ll(+2)c 4
Other chemotherapy 13 5
TOTAL 71 28
EORTC
62761 45 17
62801 13 (+3)c 5
62802 13 5
62821 10 (+4)c 4
62771 48 19
TOTAL 129 50
No chemotherapy 57 22
aThese chemotherapeutic reigmes are given in
detail in Tables VIII & VII.
bThese patients received CYVADIC
scheduled as in the adjvant trial 62771.
cPatients relapsing in control arm of adjvant
trial 62771 who received chemotherapy.
death (3 days) leaving 12 evaluable patients. There
have been 2CR, continuing at 16+ and 17+
months from the start of chemotherapy, and 4 PR
lasting 9, 3+, 4+ and 14+ months.
EORTC studies
Between 1st October 1976 and Ist July 1979
patients with advanced local or metastatic disease
were entered into EORTC protocol 62761
comparing two schedulings of the CYVADIC
regime (Table VIII). The results of this study have
been published elsewhere (Pinedo et al., 1984), and
are compared in Table IX with the results from this
centre.
Between 1st March 1980 and 25th June 1983 two
randomised phase II studies comparing the new
anthracyclines Carminomycin (Bramwell et al.,
1983) and 4'Epiadriamycin (Mouridsen et al., 1984)
with Adriamycin (Table VIII) were completed.
Table X compares the results of the multi-centre
studies with our own data.
The current first line study initiated 1st October
1982, comparing Cyclophosphamide with Ifosfa-
mide (Table VIII-protocol 62821) includes patients
who have received prior chemotherapy, in addition
to previously untreated cases. This on-going trial
has accrued 134 patients, 77 of whom are
previously untreated (March 1984).
A total of 16 patients have been treated with
single agent Ifosfamide, as described in Table VIII,COMBINED MODALITY TREATMENT OF SOFT TISSUE SARCOMA 307
Table VIII Chemotherapy regimes for advanced disease
EORTC Protocol 62761
SI-Full CYVADIC vs S2-Split CYVADIC
Cyclophosphamide 500mgm2 iv. Adriamycin 50mgm-2 i.v. day 1
Vincristine 1.4mgm-2 i.v. day 1 DTIC 250mgm-2 i.v. days 1-5
Adriamycin 50mgm-2 iV. J Cyclophosphamide 1200mgm-2 i.v.\ day 29
DTIC 250mgm-2 i.v. days 1-5 Vincristine 1.4mgm-2 i.v.J 2
Repeat every 4 weeks Repeat every 8 weeks
Protocol 62801
Adriamycin
every 3 weeks
75mgm-2 i.v. vs 4'Epiadriamycin
every 3 weeks
Protocol 62802
Adriamycin
every 3 weeks
75mgm-2 i.v.
Protocol 62821
Cyclophosphamide 2 gm-2 i.V.
as 24h infusion every 3 weeks
vs Carminomycin
every 3 weeks
20mgm-2 i.v.
vs Ifosfamide 5gm-2 i.v.
as 24h infusion every 3 weeks
CHRISTIE-CYVADIC
As SI regime protocol 62761
IFOS/MTX-. VADIC Repeated 1-2 times (omitting VCR)
Ifosfamide 5gm-2 days 1, 22, 43
24h infusion
Methotrexate 250mgm-2 i.v. days 8, 29, 50
Folinic acid 15mg oral 6hrly x 6 starting at 24h
Vincristine 1.4mgm-2 i.v. days 64, 71, 78, 85, 92, 99
Adriamycin 50 mgm-2 i.v. days 64, 78, 92
DTIC 400mgm-2 i.v. days 64, 65, 78, 79, 92, 93
Table IX Results EORTC protocol 62761.
Si- S2
FULL SPLIT
CYVADIC CYVADIC
Christie EORTC Christie EORTC
No. % No. % No. % No. %
Entered 30 125 isa 121a
Evaluable 27 84 14 78
CR 1 4 14 17 2 14 4 5
PR 7 26 18 21 1 7 7 9
NC 8 29 24 29 5 36 35 45
PD 11 41 28 33 6 43 32 41
aThis was a randomised trial, but accrual to the S2 arm
halted when it was found to be less active. The EORTC
figures show only the randomised part of the trial. The
Christie figures include all patients, but the results are no
different if only randomised patients are considered.
Table X Results EORTC protocols 62801, 62802.
Adriamycin 4'Epiadriamycin
Christie EORTC Christie EORTC
62801 No. % No. % No. % No. %
Entered 8 106 8 104
Evaluable 8 84 7 79
CR 0 0 6 7 0 0 2 2
PR 2 25 15 18 0 0 10 13
NC 5 62.5 39 46 1 14 33 42
PD 1 12.5 24 29 6 86 34 43
Adriamycin Carminomycin
Christie EORTC Christie EORTC
62802 No. % No. % No. % No. %
Entered 7 42 6 41
Evaluable 7 38 6 33
CR 0 0 1 3 0 0 0 0
PR 2 28.5 10 26 1 17 1 3
NC 3 43 18 47 2 33 15 45
PD 2 28.5 9 24 3 50 17 52
75mgm-2 i.v.308 V.H.C. BRAMWELL et al.
of whom 7 were included in EORTC trial 62821.
Nine had received prior chemotherapy. There have
been 3CR and 5PR, an overall response rate of
50%. Three of the partial remitters have relapsed
after 3, 10 and 12 months and one complete
remitter died of renal toxicity. Four patients remain
in remission although 3 are still receiving
chemotherapy.
Table XI summarises the response to first line
chemotherapy according to histology. The overall
response to first line chemotherapy regimes, single
agent and combination, was 34%. No responses
were noted in angiosarcomas or synovial sarcomas,
although only 4 patients in each group received
chemotherapy. Only one partial regression was
observed among 8 patients with fibrosarcomas.
Undifferentiated (5/8) and liposarcomas (7/14)
seemed most responsive, with 3 CR occurring in the
latter group. However, the numbers were too small
for these differences to be statistically significant.
Adjuvant trials
Christie hospital
Until 1978, patients with high grade sarcomas, in
whom there had been macroscopic removal of the
primary tumour, but who were felt to be at high
risk for relapse, received 10 cycles of adjuvant
chemotherapy with VAC (Table XII). Five year
follow up is available on 17 patients, 11 of whom
have relapsed, 3 locally, 6 with metastases and 2
with local and metastatic disease. Two patients who
experienced local recurrence have been salvaged by
amputation and one patient has had lung
metastases resected twice and is currently disease
free. There have been 8 sarcoma related deaths.
EORTC trial
Protocol 62771 (Pinedo et al., 1979) compares a
control group receiving no further treatment with a
chemotherapy group receiving CYVADIC (Table
XII), after definitive treatment of the primary
tumour by surgery and radiotherapy. Since 1st
November 1977 a total of 307 patients have been
entered into this study, 49 (16%) from the Christie
Hospital. Of this latter group, in the control arm
there have been 13 relapses in 25 evaluable patients
(52%), 3 being local, 9 metastatic and 1 at both
sites. Six patients have died of sarcoma and one of
pancreatitis (intercurrent death). In the
chemotherapy arm there have been 5 relapses in 23
evaluable patients (22%), 2 being local and 3
metastatic; these differences are not significant.
Four patients have died of sarcoma and one from
infection during a period of chemotherapy-related
myelosuppression. Three patients refused chemo-
therapy after 0,2 and 4 courses and 2 stopped
treatment, one because of myelosuppression and the
other following a myocardial infarction. There have
been 2 relapses among these 5 patients. One patient
developed acute myeloid leukaemia 12 months after
completing radiotherapy and chemotherapy for a
sarcoma of the upper arm. He remains in remission
from both sarcoma and leukaemia 26 months later.
Chromosomal analysis of leukaemic marrow was
normal.
Radiotherapy
Patients entering the EORTC adjuvant trial, 62771
received radical post-operative radiotherapy if there
was microscopic residual disease after surgery, or
less than cm margin of healthy tissue around the
tumour or when a second operation had been
Table XI Response according to histological subtype.
Histology CR PR SD PD ED Insuff. TE TOTAL
Angiosarcoma 0 0 1 3 0 0 0 4
Fibrosarcoma 0 1 1 4 1 1 0 8
Leiomyosarcoma 5 7 18 9 1 2 0 42
Liposarcoma 3 4 2 4 0 0 1 14
Neurofibro-
sarcoma 1 2 4 5 0 0 0 12
Rhabdomyo-
sarcoma 1 2 2 4 0 0 0 9
Synovial sarcoma 0 0 2 1 0 0 1 4
Undifferentiated 1 4 1 1 1 0 0 8
Malignant fibrous
histiocytoma 1 3 2 4 1 0 1 12
Miscellaneous 2 4 4 7 2 0 0 19
TOTAL 14 27 37 42 6 3 3 132a
aNumber of patients receiving chemotherapy.COMBINED MODALITY TREATMENT OF SOFT TISSUE SARCOMA
Table XII Chemotherapy regimes for adjuvant trials
EORTC-Protocol 62771
SJ-CYVADIC vs S2 No chemotherapy
Cyclophosphamide 500mgm -2 i.V.
Vincristine 1.4mgm -2 i.V. dayI Observation only
Adriamycin 50mgm-2 iV. J
DTIC 400mgm-2 i.v. days 1-3
repeat every 4 weeks x 8
CHRISTIE-VAC
Vincristine 1.4mgm-2 i.V.
Adriamycin 50mgm-2 i.v. day 1
Cyclophosphamide 500mgm-2 i.V. J
repeat every 3 weeks x 10
performed because the first was considered
inadequate. A few patients who were treated before
the trial, or were not eligible (eg. age, refusal, long
time interval from surgery) also received radical
radiotherapy. A total of 51 patients were treated in
this way and half have not relapsed. There were 4
local recurrences and 7 patients developed
metastases, while both local and distant relapse
occurred in 14 patients. An inoperable primary
tumour was irradiated in 10 patients, but 8 have
progressed locally and 8 are dead. One patient died
of metastases, but was locally controlled, one is
alive with progressive disease and the remaining
patient was treated recently. Palliative irradiation
was administered to local recurrences in 43 patients
and to mestastases in 41 patients.
Overall current status
At the time of analysis 52 patients had never
relapsed, of whom 50 were alive and 2 died free of
recurrent sarcoma. Ninety-eight (38%) of the 257
patients were alive and 72 (28%) had no evidence
of disease. A few patients had stable or partly
regressed tumours and advancing disease was
evident in 15. A total of 159 patients had died, 147
of these from malignant disease. Three patients died
from toxicity - one from infection secondary to
myelosuppression, one from renal failure while the
remaining patient developed a cardiomyopathy
after Adriamycin, followed later by Mitoxantrone.
Nine patients died from other causes which
included pancreatitis, heart failure, pulmonary
embolus, intercurrent infection and convulsions, the
exact cause of death being uncertain in two cases.
With one exception all had active disease at the
time of their demise.
Survival was not influenced by sex, but patients
less than 40 years of age did significantly better
(P<0.001) than older patients. Figure 3 illustrates
differences in survival according to site. Patients
with tumours of the limbs and trunk fared
significantly better than those with visceral
tumours. Sarcomas sited in the head and neck,
thorax and retroperitoneum were associated with a
poor prognosis (overall P<0.001). Considering the
largest histological groups, survival figures (Figure
4) were better for liposarcomas and malignant
fibrous histiocytomas than for leiomyosarcomas
and combined neurofibro- and fibrosarcomas, but
these differences were not statistically significant
(P=0.22). Histological grade proved to be the most
important prognostic factor, patients with grade I
tumours faring significantly better (P<0.001) than
those with grade II or III sarcomas (Figure 5).
Local recurrence (Figure 6) also had an
unfavourable association with survival (P<0.03).
Considering only low grade tumours (51 cases),
males seemed to fare slightly better (P=0.6) and
the age differences were still significant. Although
low grade sarcomas of the trunk and viscera
appeared to be associated with a better prognosis
than those in the limbs, and survival seemed worse
for retroperitoneal and intrathoracic tumours, the
numbers in each group were small and these
differences were not significant. It is worth
comment that all 4 patients with small (<25cm2)
grade I tumours are alive. There were no significant
differences in the other six categories. As in the
overall analysis, local recurrence and histological
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subtype did not significantly affect survival. With 4
exceptions low grade tumours were treated by wide
resection.
For high grade tumours age, sex, histological
subtype and local recurrence did not influence
survival. Patients with limb sarcomas had a
significantly (P<0.02) better prognosis than the
remainder (Figure 7) and amputation was
associated with a better outcome than local
resection (Figure 8). Tumours of increasing size
were associated with a worse prognosis (P<0.002).
Patterns ofrelapse
At the time of analysis 143 (56%) patients had
experienced one or more local recurrences and 159
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Figure 7 Survival in patients with high grade tumours
according to site.
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Figure 8 Survival in patients with high grade tumours
according to surgical procedure.
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(62%) had developed metastatic disease. In 96 cases
(37%) both ultimately occurred. Table XIII
summarises the incidence of local recurrence and
metastasis according to histology. Although
neurofibrosarcomas and fibrosarcomas had the
highest rate of local recurrence (71%), there were
no significant differences between histological types.
Rhabdomyosarcomas (79%) synovial sarcomas
(79%) undifferentiated (75%) and leiomyosarcomas
of the uterus (79%) showed an increased propensity
for metastasis, whereas fibrosarcomas (39%) and
liposarcomas (43%) metastasised less frequently.
All 6 patients with mixed mesodermal sarcomas of
the uterus have died of disease, but 4 of 5 patients
with endometrial stromal tumours are alive, 3 being
disease free.
Table XIV illustrates the pattern of local
recurrence and metastasis according to site.
Table XIII Incidence local rec
histolo
Although metastases were less common from sites
in the head and neck (45%) and retroperitoneum
(43%) local recurrence, (82% and 67% respectively)
often not amenable to further surgery, was a
particular problem. Visceral sarcomas had a low
rate of local recurrence (41%), but a high incidence
of metastases (81%). Dissemination was surpris-
ingly frequent in distal lower limb tumours (92%)
but this incidence may have been distorted by small
numbers.
The sites of first metastasis are summarised in
Table XV. A number of patients relapsed at several
sites simultaneously. The dominant site of
recurrence was pulmonary (57%) followed by
intraabdominal disease (17%) usually related to
visceral sarcomas. Lymph node metastases occurred
in 11% of patients and skin/subcutaneous, bone
and liver metastases were also uncommon (8-9%).
ourrence and metastases related to
)gical type.
Local recurrence Metastases TOTAL
Histology No. % No. % No. %
Angiosarcoma 6 60 6 60 10 4
Fibrosarcoma 12 71 7 39 17 7
Leiomyosarcoma 35 51 45 66 69 27
Liposarcoma 18 49 16 43 37 14
Neurofibro-
sarcoma 15 71 14 67 21 8
Rhabdomyosarcoma 9 64 11 79 14 5.5
Synovial sarcpma 8 62 11 79 13 5
Undifferentiated 8 67 9 75 12 4.5
Malignant fibrous
histiocytoma 16 59 15 56 27 11
Miscellaneous 16 43 25 66 37 14
TOTAL 143 56 159 62 257 100
Table XIV Incidence local recurrence and metastases related to site.
Local recurrence Metastases Total
Site No. % No. % No. %
Head & neck 9 82 5 45 11 4
Distal upper limb 1 20 3 60 5 2
Proximal upper limb 8 40 11 55 20 8
Distal lower limb 7 54 12 92 13 5
Proximal lower limb 44 60 43 59 73 28
Trunk 20 61 20 61 33 13
Retroperitoneum 20 67 13 43 30 12
Visceral 22 41 44 81 54 21
Intrathoracic 5 63 3 38 8 3
Other 7 70 5 50 10 4
TOTAL 143 56 159 62 257 100COMBINED MODALITY TREATMENT OF SOFT TISSUE SARCOMA 313
Table XV Sites of first metastasis.
Patients (159)
Sites No.a %
Lymph nodes 18 11
Skin-subcutaneous 14 9
Bones 14 9
Lungs 91 57
Intra-abdominal 27 17
Liver 12 8
Cerebral 1 0.6
Bone marrow 1 0.6
Other 7b 4
aMore than one site per patient.
bBreast 5 Extradural 2.
Discussion
Many reviews of large series of sarcomas have
appeared in the literature. Such series comprise
patients referred to specialist centres for
management, and their composition will reflect the
major interest of the unit. Thus referral patterns to
a department of radiotherapy may differ con-
siderably from those to a department of surgery.
Multi-modality management, with collaboration
between departments dealing with surgery, radio-
therapy and chemotherapy, is increasingly common
and some recent series from the United States
reflect this policy (Lindberg et al., 1981,
Weisenberger et al., 1981 and Rosenberg et al.,
1981b). The Christie Hospital is a specialist cancer
centre dealing predominantly with radiotherapy and
chemotherapy. Although specialist surgery is
available, this has not generally included the
management of sarcomas. Thus the composition of
this series will reflect a pattern of referral of
patients who might be suitable for chemotherapy or
radiotherapy, and consequently will differ
considerably from earlier British series (Cade 1951;
Windeyer et al., 1966; Coe et al., 1981). Although
between 1974 and 1976 comparatively few patients
(7-25%) were referred for consideration of
adjuvant therapy, this proportion has steadily risen,
reaching a peak of 57% in 1982, although the 1983
figures were lower (Figure 1).
The American Joint Committee for Cancer
Staging and End-Results (AJC), over an 8 year
period, collected a series of 1215 cases of soft
sarcoma from 13 institutions within the United
States. An anlysis of these cases has been published
(Russell et al., 1977) and the present series will be
compared with this, with occasional reference to
relevant British series.
A male to female ratio of 1.5: 1 is unusual, most
large series reporting an equal distribution, and
there is no clear reason for this bias. The median
age, 54 years, is higher than that in the AJC series
- 43 years - but agrees with a report of 191 cases
collected by the National Soft Tissue Sarcoma
Registry (Mettlin et al., 1982) in which the median
age was 58.5 years.
Most patients (79%) presented with a mass. In
many cases it was painless, but vague aching
discomfort often occurred. Severe pain was
uncommon, but a limb sarcomas was often
associated with neurological deficit due to pressure
on major nerves. The high incidence of vaginal
bleeding (13%), urinary symptoms and abdominal
distension reflects inclusion of a significant
proportion (16%) of uterine sarcomas. Although
common with metastatic disease, respiratory
symptoms from primary sarcomas were rare, but in
one patient haemoptysis due to lung metastases led
to the discovery of an asymptomatic primary
uterine sarcoma. Delay in diagnosis is illustrated
by the wide range (0-238 months) and long mean
interval (12.4 months) between first symptoms and
definitive treatment of the primary tumour, as
patients (and sometimes their doctors) often
ignored painless lumps until other symptoms
supervened.
In comparison with the AJC series and that of
Cade (1951) there were fewer extremity tumours,
44% vs. 52-53%. Higher proportions of limb
sarcomas, 66-71%, were present in two British
radiotherapy series (Windeyer et al., 1966, Coe et
al., 1981). Visceral sarcomas which comprised the
second largest group in our series are not separately
classified in the AJC report, and it is not clear
whether they have been included with sarcomas of
the trunk or completely excluded. Tumours of the
thigh and buttock, together with retroperitoneal
sarcomas predominate in all large series of soft
tissue sarcomas, and this is no exception. In
agreement with other series, liposarcomas pre-
dominate in the thigh and buttock (26%) and we
concur with other findings in the AJC report eg.
leiomyosarcoma is the commonest histological type
in the retroperitoneum (40%) and synovial sarcoma
is predominantly a tumour of the lower extremity -
11 of 13 cases. The four dominant histological
types in most early surgical and pathological series
(Shiu et al., 1975, Gerner & Moore, 1975 and
Rosenberg & Glatstein, 1983) including the AJC
study are fibrosarcoma, liposarcoma and rhabdo-
myosarcoma. Malignant fibrous histiocytoma is
becoming increasingly recognised as a separate
entity (Weiss & Enzinger 1978; Rantakokko Ekfors,
1979; Kearney et al., 1980), and features in the AJC
series. It is likely that many cases previously
classified as fibrosarcoma or rhabdomyosarcoma
now fall into this group. In 1978 the South West314 V.H.C. BRAMWELL et al.
Oncology Group published the results of a
pathological review of 130 cases entered into a
chemotherapy trial for advanced disease (Baker &
Benjamin 1978). Malignant fibrous histiocytoma
(22%), leiomyosarcoma (20%) and fibrosarcoma
(10%) were the commonest histological subtypes.
The EORTC have found a similar distribution in
their CYVADIC study (Pinedo et al., 1984). In
view of the high proportion of patients with
advanced disease at presentation to the Christie
(64%), and the high incidence of visceral sarcomas,
it is not surprising that leiomyosarcoma (26%),
liposarcoma (14%) and malignant fibrous
histiocytoma (11%) are the dominant histological
subtypes in this series. Malignant fibrous
histiocytoma is probably under-represented as cases
in this study have been reviewed over a 10 year
time period. Fibrosarcoma, synovial sarcoma and
rhabdomyosarcoma were the commonest
histological diagnoses among sarcomas of the
extremities seen at the Christie in the 20 years
preceding this study (unpublished data). In any
series biased towards advanced disease, there is
likely to be a greater proportion of high grade
tumours (67% in this series). Intermediate grade
sarcomas were uncommon (6%) and their division
from high grade tumours seems to have little
clinical significance.
Some studies (Suit et al., 1975; Weiss & Enzinger,
1978, Rantakokko & Ekfors, 1979) have suggested
that size is related to prognosis, although others
disagree (Markhede et al., 1982). In their proposal
for a new staging system, Russell et al. (1977) have
subdivided stages I to III into A (tumour<5cms)
and B ( > 5cms), but analysis of their collected
cases does not demonstrate a clear survival
advantage for smaller tumours. Tumour size was
not recorded in approximately one third of cases. A
similar problem arose in this series as clinical size
was particularly poorly recorded and, for various
reasons, pathological size was missing in more than
one third of patients. Thus any relationship
between size and recurrence/survival must be
interpreted with caution. The high incidence of
local recurrence and metastases in tumours of
unknown size is not surprising as this group
includes a large proportion of tumours which could
not be resected or only removed piecemeal, which
will inevitably recur. The frequency of local
recurrence was unrelated to size, possibly because
local resection was the commonest surgical
procedure, which in many cases took the form of
"shelling out", or removal with minimal margins.
Often these small tumours were thought to be
benign, and even when the true histology was
apparent, surgeons were reluctant to reoperate.
Unfortunately excisional biopsy may cause quite
wide seeding in the operative site, and later radical
surgery may still fail. Pre-operative diagnosis of
larger sarcomas meant that appropriate initial
surgery was more likely, and may account for the
suprisingly low incidence of local relapse in
tumours >400cm2. There were Ill limb sarcomas,
of whom 34 (31%) had been treated by amputation
at the time of referral to the Christie. In many of
these, ablative surgery had been performed after
one or more local recurrences. Reviewing the local
resections it was clear from the operation notes that
compartmental resections was rarely performed.
Simon & Enneking (1976) achieved a 98% local
control rate in 46 patients with limb sarcomas
treated by radical local resection or amputation,
and judged to have had an adequate operation.
However, amputation was necessary in 29 patients
and all eight patients who had inadequate
operations experienced local recurrence.
Approximately half the patients in this series
were entered into collaborative European trials of
chemotherapy, and a further quarter received
chemotherapy in local pilot studies. In trials
accruing small numbers of patients, there may be
considerable variation in response rates due to
heterogeneity in patient populations with respect to
factors such as age, performance status, histological
type and grade and tumour burden. This is
illustrated by response rates to the same CYVADIC
combination (Table VIII). The overall response rate
among all patients entered into EORTC protocol
62761 was 38%, but for Christie patients entering
the trial (32% of the total evaluable) it was lower
at 30%. In contrast, the response rate in the
Christie pilot study was 47%. If all Christie patients
are combined the response rate is 37%. Although
overall response to the S2 split regime was
disappointing, 2 patients with the most durable
complete remissions (39, 54 months) received this
form of chemotherapy. In the anthracycline studies,
the response rate to Adriamcyin among Christie
and EORTC trial patients was remarkably
consistent between 25-29%. In protocol 62801,
there was no significant difference in response rate
between 4'Epiadriamycin and Adriamycin, although
the former was slightly less toxic (Mouridsen et al.,
1984), but we did not obtain any responses in 7
evaluable patients. In contrast we observed the only
remission on Carminomycin in protocol 62802
(Table X).
Our response rate (50%) to a new alkylating
agent, Ifosfamide, is very encouraging. Even if one
complete remitter with Ewing's sarcoma of soft
tissues, a highly responsive tumour, is removed the
results are similar to these reported from the Royal
Marsden (Stuart-Harris et al., 1983). Although the
numbers are small, they are supported by dataCOMBINED MODALITY TREATMENT OF SOFT TISSUE SARCOMA
from the 13 patients receiving Ifosfamide in
combination with Methotrexate, 6 of whom have
responded.
In most chemotherapy trials, no significant
differences in response according to histological
subtype have emerged because of relatively low
response rates and small numbers in each group
(Pinedo et al., 1984; Presant et al., 1981; Schoenfeld
et al., 1982). Reporting results in 125 patients, Yap
et al. (1980) found neurofibrosarcoma, rhabdo-
myosarcoma, leiomyosarcoma, fibrosarcoma and
angiosarcoma to be most responsive, which
conflicts with our findings. It is likely that in both
studies these differences have occurred by chance.
Considering adjuvant chemotherapy, data from
the small pilot study of VAC chemotherapy are
difficult to interpret. The numbers are small and
there is no comparative control group. Patients at
high risk for recurrence - eg. tumour spillage at/
operation, sites where radical resection was
difficult, high grade tumours - were given adjuvant
therapy, but local relapse has occurred in 29% and
metastasis in 47% of cases. The EORTC adjuvant
trial 62771 is still accruing patients and it is
premature to report results. Among the Christie
entries fewer patients have developed metastatic
disease in the chemotherapy arm, 3 compared with
9 in the control arm, (although there was one
chemotherapy death). This reduced incidence of
metastases is in agreement with two randomised
studies of adjuvant chemotherapy reported in the
United States (Edmonson et al., 1982; Rosenberg et
al., 1983), but it would be unwise to draw firm
conclusions from a small subgroup of a larger
randomised trial which is still in progress. Follow-
up is too short to exclude the possibility that
postponement of recurrence due to chemotherapy is
responsible for the observed difference. Criteria for
ensuring that patients were truly disease free at
entry into protocol 62771 were much stricter than
for the VAC study. Survival is similar in both arms
but there have been few events. Difficulties have
been encountered in administration of the
prescribed chemotherapy, either due to myelo-
suppression or patients' refusal because of vomiting
and alopecia. Although it is possible that our case
of acute myeloid leukaemia was induced by
chemotherapy, the short time interval, normal
karyotype and good response to chemotherapy are
atypical features of secondary leukaemia.
Although soft tissue sarcomas have often been
considered radioresistant, there are many accounts
in the literature of good regressions, and even
"cures" of primary tumours, and satisfactory
palliation of metastatic disease using radiotherapy
(McNeer et al., 1968, Suit & Russell, 1975). In this
study the results of irradiating inoperable primary
tumours were poor, but some of these were large
retroperitoneal tumours placing restrictions on the
tolerable dose. The rate of local control following
radical post-operative radiotherapy (64%) was
disappointing, although similar to another British
series (Coe et al., 1981), in comparison with some
reports (Rosenberg et al., 1981b, Lindberg et al.,
1981, Liebel et al., 1981), but this was an unselected
group of patients with tumours at all sites.
Inadequate prior surgery, often limited to excisional
biopsy, may have influenced the results.
The high rate of metastasis (62%) and poor
survival (38%) is biased by referral patterns. A few
patients were moribund at the time of presentation
to the Christie. Remissions in excess of 2 years have
been observed in only 4 patients with metastatic
disease, one relapse occurring after four and a half
years. Unfortunately we have not seen remissions
continuing beyond 5 years as reported by Yap et al.
(1983). The results of current regimes of
combination chemotherapy remain disappointing,
and new approaches are desparately needed. As
soft tissue sarcomas have a propensity for relapse
in the lungs, which may be the only site of disease,
combined surgery and chemotherapy is often
feasible and good results have been reported
(Benjamin et al., 1981, Karakousis et al., 1982). To
date we have treated 7 patients in this way, 3 of
whom are disease free (one requiring a second
thoracotomy) although the remaining 4 have
relapsed and died. We intent to pursue this line of
management in suitable patients.
Rhabdomyosarcomas and synovial sarcomas are
usually considered to be aggressive tumours of high
metastatic potential (Morton & Eilber, 1982,
Enzinger & Weiss 1983). This has been
confirmed in this series. For fibrosarcomas, a
high rate of local recurrence but reduced incidence
of metastases is consistent with other reports
(Pritchard et al., 1974, Enzinger & Weiss 1983), but
the numbers are small. Although pleomorphic
liposarcomas often disseminate, well differentiated
and myxoid types are more common and a reduced
incidence of metastasis in this series is consistent
with other reports (Reszel et al., 1966, Enzinger &
Weiss, 1983). Leiomyosarcomas of the uterus,
particularly those of high grade, have a dismal
prognosis (Spiro & Koss 1965, Hart & Billman
1978), confirmed in this series. Uterine mixed
mesodermal sarcomas seemed to do particularly
badly whereas endometrial stromal sarcomas fared
better, but numbers were small. Salazar and
coworkers (1978b) showed a higher rate of relapse
in mixed mesodermal compared with leiomysar-
comas of the uterus, although the former usually
presented at a more advanced stage. Problems
associated with radical removal account for high
315316 V.H.C. BRAMWELL et al.
rates of local recurrence in the head and neck and
retroperitoneum, and many patients probably die of
local disease before they can develop metastases.
In this study, the most significant factor
influencing survival was histological grade, a
finding that has been extensively documented in the
literature (Markhede et al., 1982, Rantakokko &
Ekfors, 1979; Russell et al., 1977; Shiu et al., 1975,
Rosenberg & Glatstein, 1983 and Suit et al., 1975).
Russell et al. (1977), reporting an analysis of the
AJC series of 1215 cases, proposed a staging system
principally based on this factor. The other
significant prognostic factors in this series were
primary site and size. As limb and visceral
sarcomas are more amenable to radical resection
than tumours of the head, neck and trunk, their
better prognosis is not surprising and is well
documented (Lindberg et al., 1975; Rosenberg et
al., 1981b). The relevance of size has been discussed
earlier. Local recurrence was correlated with a
poorer survival and is in agreement with much of
the published literature. The finding that histo-
logical subtype is unimportant, particularly when
the influence of grade is removed, is consistent with
the published literature, and reflects uncertainties in
determining histogenesis in many tumours. For
high grade tumours amputation was associated with
a better outcome than local resection. The number
of patients with low grade tumours treated by
amputation was too small to assess the relative
merits of these procedures. The better overall
survival for younger individuals was not evident for
high grade tumours. Younger patients may be more
likely to receive radical treatment which may
influence survival for low grade tumours. A high
rate of metastasis in grade III tumours, with
ultimate demise of the patient, is unlikely to be
related to age.
As anticipated the commonest first site of
metastasis was pulmonary, occurring in 58% of
cases. Intraabdominal disease usually took the form
of peritoneal and omental seeding from visceral
tumours, although it was not always possible to
determine the exact sites of tumour. At least
initially, other sites such as lymph nodes, liver and
bone were less common, although we know from
post mortem studies that utlimately widespread
dissemination may occur (Kavanagh 1980) and
even cerebral metastases are more common after
chemotherapy (Bryant & Wiltshaw 1980; Espana et
al., 1980).
We would like to thank Gillian Wood and Vivien
Forsythe for invaluable assistance with data handling, and
Eileen Morgan and Barbara Whittle for typing the
manuscript.
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